Pharmaceutical - Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 217 results

Novartis announces positive results for secukinumab in psoriatic arthritis

Novartis announces positive results for secukinumab in psoriatic arthritis

17-11-2014

Swiss drug major Novartis has announced results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

EMA responds to Ombudsman questioning of AbbVie trial redactions

13-11-2014

The European Medicines Agency says it has taken note of the European Ombudsman’s recent remarks on…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulationResearch

Cut number of rheumatoid arthritis drugs and reduce side effects, says Belgian research

Cut number of rheumatoid arthritis drugs and reduce side effects, says Belgian research

10-11-2014

A two-year study into rheumatoid arthritis conducted at university hospitals in Belgium has shown that…

Anti-Arthritics/RheumaticsBelgiumLeflunomidemethotrexatePharmaceuticalResearch

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

07-11-2014

The UK’s National Institute for Health and Care Excellence is consulting on provisional recommendations…

Anti-Arthritics/RheumaticsPfizerPharmaceuticalRegulationUKXiapex

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

03-11-2014

Although 80% of rheumatologists surveyed by data and research firm Decision Resources Group prescribe…

Anti-Arthritics/RheumaticsBiosimilarsGlobalPfizerPharmaceuticalResearchXeljanz

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

01-11-2014

Just a couple of weeks after abandoning its $54 billion “tax inversion” motivated takeover of Ireland-headquartered…

AbbVieAnti-Arthritics/RheumaticsFinancialHumiraPharmaceuticalShireUSA

New Zealand proposal for sole supply of Remicade in DHB hospitals

New Zealand proposal for sole supply of Remicade in DHB hospitals

31-10-2014

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesceftaroline fosamilFinancialJanssen-CilagJohnson & JohnsonNew ZealandPharmaceuticalPricingRemicade

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

23-10-2014

Swiss drug major Novartis says its investigational drug AIN457 (secukinumab) has achieved the primary…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Horizon Pharma buys US rights to Nuvo’s Pennsaid for $45 million

19-10-2014

Canadian specialty drugmaker Nuvo Research says it has completed the sale of its osteoarthritis pain…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingMallinckrodtNuvo ResearchPennsaidPharmaceuticalUSA

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

AbbVie gains expanded approval for Humira by FDA

AbbVie gains expanded approval for Humira by FDA

06-10-2014

US drugmaker AbbVie has received approval from the US Food and Drug Administration for an extension of…

AbbVieAnti-Arthritics/RheumaticsHumiraPharmaceuticalRegulationUSA

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Merck’s odanacatib succeeds in Ph III osteoporosis trial

Merck’s odanacatib succeeds in Ph III osteoporosis trial

16-09-2014

US pharma giant Merck & Co has announced positive data from the pivotal Phase III fracture outcomes study…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalResearchWomen's Health

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS

11-09-2014

US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Roche’s RoActemra gains EU approval for use in early RA

Roche’s RoActemra gains EU approval for use in early RA

08-09-2014

The European Commission has approved Swiss pharma major Roche’s RoActemra (tocilizumab) for use in…

ActemraAnti-Arthritics/RheumaticsEuropeInterleukin 6PharmaceuticalRegulationRoActemraRoche

Novo Nordisk pulls out of inflammatory disorders research

Novo Nordisk pulls out of inflammatory disorders research

02-09-2014

Danish diabetes care giant Novo Nordisk says it has decided to discontinue all its R&D activities within…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceutical

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

01-09-2014

Belgian drug developer Ablynx has expanded its relationship with China’s Eddingpharm, by granting the…

AblynxAnti-Arthritics/RheumaticsChinaEddingpharmLicensingMarkets & MarketingozoralizumabPharmaceutical

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11-08-2014

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Roche’s…

Anti-Arthritics/RheumaticsImmunologyImmunosuppressantsNHSPharmaceuticalRegulationRoActemraRocheTocilizumabUK

Pfizer granted European approval for Enbrel in early-stage inflammatory joint disease

Pfizer granted European approval for Enbrel in early-stage inflammatory joint disease

06-08-2014

US pharma giant Pfizer has been granted a license extension by the European Commission for Enbrel (etanercept)…

Anti-Arthritics/RheumaticsArthritisChronic, lifelong inflammatory diseaseEnbrelPfizerPharmaceuticalRegulationSpondyloarthropathyUSA

US PhRMA firms developing nearly 100 new medicines for arthritis

US PhRMA firms developing nearly 100 new medicines for arthritis

28-07-2014

The USA’s biopharmaceutical research companies are developing 92 innovative new medicines to help the…

AnatomyAnti-Arthritics/RheumaticsBiopharmaceutical researchHealthHealth Medical PharmaMedicinePharmaceuticalResearchUSA

Medac’s Rasuvo approved for RA while Antares’ injunction is denied

Medac’s Rasuvo approved for RA while Antares’ injunction is denied

14-07-2014

USA-based Medac Pharma, a wholly-owned subsidiary of privately-held German firm medac GmbH, says that…

Antares PharmaAnti-Arthritics/RheumaticsLegalMedac PharmaPharmaceuticalRasuvoRegulationUSA

1 to 25 of 217 results

Back to top